UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of the webcast will be available on the Company’s website for approximately 30 days.
About
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product and the investigational treatment UGN-102 (mitomycin) for intravesical solution in development for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005334/en/
INVESTOR CONTACT:
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: